DPP4 and hydrops fetalis: Contrary to the concerns about an increased cardiovascular risk with the use of DPP-4 inhibitors, which were triggered by randomized controlled trials with placebo control, our study found a protective effect on cardiovascular outcome, particularly against HF, with the use of the active comparator drug glimepiride.